acmefirewoodis...(put something here)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Neurorestoration animal data results in three weeks?
Why the delay?
What happened to the 12/22 date?
I still can't find verification that it's true.
Google "Owen Garrick" and the AMA Foundation and post what you find.
Thanks in advance.
Penny stocks are volatile. That's part of the fun of trading them.
I suggest placing some limit buy orders at low prices to take advantage of days with volatility such as yesterday's.
Penny stocks typically don't go straight up.
GLTA
Thanks for the update.
He is president of the "foundation" and not the "association".
Someone had posted that he was president of the AMA when they should have posted that he is president of the AMAF.
Similar to someone being President of the United States and some one being president of the local chapter of "Friends of the President of the United States." :)
Not that it's misleading.
Someone should contact the AMA and let them know that the wrong individual is pretending to be the AMA president:
http://www.ama-assn.org/ama/pub/ama-president-blog.page
When was he president? The original press release in 2011 stated that he was then the President of the AMA which wasn't true.
Obviously the information currently on the company's website is misleading since he is not the President of the AMA currently.
I'm certain the company will correct this as soon as Gerald reads my e-mail this morning.
Is the President of the AMA really on the company's advisory board?
From the company's website:
Dr. Owen Garrick
Advisor to the Board of Directors
Dr. Garrick joins Amarantus with over 20 years of pharmaceutical and biotechnology experience. He currently serves as the Chief Operating Officer at Bridge Clinical Research and is President of the American Medical Association Foundation. Prior to that, he was Director of Corporate Strategy and Business Development at McKesson Corporation. Dr. Garrick was Executive Director and Co-Head of Mergers & Acquisitions at Novartis Pharmaceuticals where he oversaw company acquisitions, hybrid equity/license rights deals, mature product divestments and venture investments in biotechnology companies. Prior to Novartis, Dr. Garrick was an associate at Goldman Sachs in New York. Dr. Garrick received his MD from Yale School of Medicine and earned his MBA from Wharton School of Business. He holds an AB from Princeton University, where he has served on the national fund raising board.
Can anyone find any reference to him being the President of the American Medical Association Foundation?
The following link suggest someone else is and was the president of the AMA:
http://www.ama-assn.org/ama/pub/news/news/2012-10-12-wilson-named-wma-president.page
Possibly I didn't spend enough time searching for an answer.
Must be an oversight of mine or the Amarantus Bioscience's vetting process.
Looks like a "GREEN" sunset ahead!!!!!
If the shorts would stop selling. :(
Does AMBS still trade on the Berlin/Bremen exchange?
If so does anyone have a link to check on price and volume?
Thanks in advance for a helpful reply.
Buy a few shares. Let's close it above six cents.
Never sell AMBS shares at a loss. These occasional bear raids will happen as the shorts need millions of shares to cover. Don't panic and give away your shares. Add a few more shares on the dips.
This is just starting a long term uptrend especially since it is substantially undervalued.
I hate to see individuals get scared and sell shares in a company that is just becoming known to the market.
$1.00 next year is realistic.
All IMHO.
It seems that the enthusiasm surrounding Afrezza is waning. Possibly it's the years of trying to get it approved.
It will be interesting to see how the share price is impacted when the announcement is made tomorrow that the number of authorized shares is increased from 350,000,000 to 550,000,000.
May drop below $2.00.
I think it closes at .0595 with an end of the day run-up.
Just a hunch. :)
p.s. Interesting weeks ahead.
GLTA
This is one press release away from .20 and I expect it soon.
The company's management is doing everything to make the company a huge success.
The "potential" discounted value of the patented MANF technology should have the company with a current market cap in the $50,000,000 range or about .25/share.
It's tremendously undervalued with substantial upside.
That is why I'm adding on the dips.
Fair value is currently in the .17-.18 range.
The next positive press release will take it there.
Word is just getting out to the market about the tremendous potential that the company's patented MANF technology offers to the drug industry.
Buy shares today at the bottom.
Green close today would work for me.
Added a few shares at .0485 today. :)
Free $$$$$$$$$ is always appreciated.
$1.00 is 2013 is my target.
p.s. We're overdue for a press release from the company. :)
Either you believe in the company and its management and the tremendous potential that its patented MANF technology offers or you don't.
AMBS is the most undervalued bio-tech in the market.
Expecting to be above .07 by Friday and headed to .10.
GLTA
Fair value is .17 currently.
Day traders are playing today.
This is tremendously undervalued.
The company's patented MANF technology will lead to a number of blockbuster drugs.
Stocks move higher then there's some profit taking and then they continue higher.
Either you're a believer or you're not.
The ignore feature works great. All one has to do is click on your board name and "ignore this member" appears.
You are now "ignored".
I suggest others do the same.
.20-.25 by 12/31/2012.
.20-.25 on 12/31/2012 seems realistic.
I expect the MANF comparative study data before then.
This is the most undervalued bio-tech in the market.
Fair value is .17 based on current information.
"Big pharma" development partnership(s) or buyout in 2013.
$1.00 or more.
Major drug companies have billions of dollars to spend on acquisitions or partnerships.
AMBS is the most undervalued bio-tech in the market.
.20-.25 by 12/31/2012.
The co-founder of Amgen is 100% correct when he stated that the company's MANF technology would be worth billions and be a blockbuster drug.
It's the most undervalued bio-tech in the market.
Fair value is currently .17.
It will catch up within a week or two.
Expecting a press release from the company this week regarding the MANF comparative study results.
Should move it above .10 by Friday.
Good luck to all.
Nice consolidation at .06. The next press release from the company takes it to .10.
The penny flippers are leaving the building.
Up trend is firmly in place.
Substantially undervalued here.
.17 is fair value.
.20 on 12/31/2012.
Over $1.00 in 2013.
Most undervalued bio-tech in the market.
The shorts are impotent here. It's obvious that they are losing their ability to take this lower.
Enjoy the ride up.
Opens above .08 tomorrow.
Word is getting out to the market.
Reasonable market cap takes the share price to the .17-.20 range.
Where are the shorts going to find over 100,000,000 shares?
Buy/add more shares today.
Family fortunes are made on opportunities such as the one that Amarantus offers.
Amgen was once an eight cents stock and now it's at $90.00. Rather ironic that one of its co-founders is now on the company's advisory board.
Years from now when your grandchildren ask you where the family wealth originated you can tell them that you bought shares of AMBS for under a dime. They probably won't believe you but they'll still appreciate the lifestyle that it allowed them to have.
VRML went from a penny to $35.00. It was based on a substantial short squeeze. Partnership news didn't enter the picture as I recall.
It was at a penny because bankruptcy was the company's next move but fortunately an F.D.A. approval rescued it.
The sector is somewhat irrelevant.
The company is tremendously undervalued based on the potential that the MANF technology offers.
"Big pharma" drug companies are flush with cash and Amarantus would be a perfect target for a partnership or a buyout.
$1.00 may be on the low side.
Closing above .075 today. Setting up for a major run-up at the end of today's trading session.
.12-.15 by Christmas. Ho!!! Ho!!! Ho!!!
Shorts need over 100,000,000 shares. :(
A reasonable market cap is $35,000,000 which equates to about .17/share.
That is where this should be currently.
It's substantially undervalued based on available information.
Shorts need 100,000,000 shares.
.20-.25 on 12/31/2012.
Most undervalued bio-tech in the market currently.
VRML went from one cent to $35.00 when the shorts guessed wrong.
AMBS is the most undervalued bio-tech in the market currently.
If you're reading this post then you know about the tremendous upside that buying at the current share offers to an investor.
Anyone who is on the sidelines waiting for a pullback is going to be sadly disappointed.
There are millions of shares "short" that will have to be bought as the share price continues to climb.
A realistic share price based on currently available information would be in the .20-.25 range with an up trend in place.
Remember that investing in a stock at the bottom is a very good thing and you now have the opportunity to do so.
Exciting months ahead for AMBS shareholders.
The company's management team is "top shelf" and surrounding themselves with some of the best advisors in the bio-tech industry.
I think .20-.25 is realistic for next week.
There are millions of "short" shares that have to be bought with the shorts now competing against new buyers who are just finding out about the tremendous upside that AMBS offers.
$1.00 is probably three months away. It's just a matter of time before a "big pharma" company comes forth with a development partnership with a substantial upfront cash payment. A buyout at a much higher price is also possible longer term.
Amgen (AMGN) traded in the eight cent range when the company was first started. Now it is in the $90.00 range.
I can't understand why anyone would sell/short a $1.00 stock for five cent. :(
"One Med Forum"
http://finance.yahoo.com/news/amarantus-bioscience-present-onemedforum-2013-125200574.html
Buy at the open tomorrow before it starts running higher.
Shorts still need millions of shares to cover.
Positive data from the MANF comparative study triples the share price overnight.
.20-.25 by 12/31/2012.
"Big pharma" partnership(s) and licensing agreements takes it over a $1.00 in 2013.
Interesting times ahead for the company's shareholders.
Word is getting out to the market.
p.s. Expect a few more Seeking Alpha articles about the company's potential in the next ten days.
The market is just becoming aware of the tremendous potential that the company's patented MANF technology has to offer.
The company's management is doing an excellent job of bringing well known and respected individuals on board to help guide them in making the company a tremendous commercial and financial success for its shareholders.
Take the time to read about the individuals who are on the company's advisory board:
http://www.amarantus.com/about-us/corporate-advisory-board.html
A "big pharma" development partnership in 2013 takes this above $1.00. It's only a matter of time before it happens.
The shorts need millions of shares to cover with no where to find them. Hold on to your cheap shares. AMBS is tremendously undervalued.
Interesting months ahead for the shareholders.
p.s. In its beginning Amgen (AMGN) was trading in the eight cents price range. Today it is trading at almost $90.00. Don't think it can't happen here.
I think .20-.25 is realistic for next week.
$1.00 is probably three months away.
"One Med Forum"
http://finance.yahoo.com/news/amarantus-bioscience-present-onemedforum-2013-125200574.html
Closes above .10 tomorrow.
The company's patented MANF technology is the real deal.
Don't be on the sidelines when the MANF comparative study results are released.
.20-.25 on 12/31/2012.
Minimum of $1.00 in 2013.
Shorts need millions and millions of shares to cover.
The co-founder of Amgen didn't join the company's advisory board on a whim. He believes that the MANF technology could generate billion is future revenues.
"Big pharma" partnerships and/or licensing agreements on the horizon.
One Med Forum:
http://finance.yahoo.com/news/amarantus-bioscience-present-onemedforum-2013-125200574.html
.065-.07 tomorrow.
.10-.12 by Friday.
MANF comparative study data release takes it to the .20 range immediately.
Shorts are going to get burned very soon.
IMHO.